| human | Q5 |
| P496 | ORCID iD | 0000-0003-2882-1962 |
| P108 | employer | AskBio (United States) | Q30286896 |
| University of Pennsylvania | Q49117 | ||
| P734 | family name | Lacey | Q24469938 |
| Lacey | Q24469938 | ||
| Lacey | Q24469938 | ||
| P735 | given name | Simon | Q4117588 |
| Simon | Q4117588 | ||
| P106 | occupation | medical researcher | Q15401884 |
| P21 | sex or gender | male | Q6581097 |
| Q91189738 | A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells |
| Q42424217 | A comparative study of Merkel cell, BK and JC polyomavirus infections in renal transplant recipients and healthy subjects |
| Q45976106 | A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation. |
| Q45946525 | A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. |
| Q61954948 | Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers |
| Q51736472 | Activity of Mesothelin-specific Chimeric Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. |
| Q64120245 | Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma |
| Q52579654 | Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. |
| Q35810028 | Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. |
| Q47604546 | Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. |
| Q38342331 | Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. |
| Q102056914 | Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals |
| Q92522868 | B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma |
| Q38082224 | Biomarkers in T-cell therapy clinical trials |
| Q88480236 | Biomarkers in chimeric antigen receptor T-cell therapy |
| Q60047537 | CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success |
| Q92039571 | CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration |
| Q35114369 | CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. |
| Q85544183 | CRISPR-engineered T cells in patients with refractory cancer |
| Q47764871 | Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| Q46690133 | Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants |
| Q47622360 | Characterization of host immunity to cytomegalovirus pp150 (UL32). |
| Q35182714 | Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice |
| Q36284584 | Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma |
| Q47332598 | Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas |
| Q45878789 | Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer |
| Q29617588 | Chimeric antigen receptor T cells for sustained remissions in leukemia |
| Q41429394 | Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia |
| Q35842287 | Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant |
| Q36349583 | Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy |
| Q45417971 | Cross-reactive CTL recognizing two HLA-A*02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals |
| Q33930455 | Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. |
| Q39385892 | Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. |
| Q50091857 | Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights |
| Q46025567 | Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. |
| Q47626470 | DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice |
| Q97566149 | Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications |
| Q96223314 | Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions |
| Q52715364 | Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. |
| Q39490642 | Development of infectious recombinant BK virus |
| Q100954027 | Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children |
| Q58889356 | Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells |
| Q88884600 | Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication |
| Q30827633 | Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies |
| Q98171149 | Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer |
| Q104143710 | Endothelial Biomarkers Are Associated With Indirect Lung Injury in Sepsis-Associated Pediatric Acute Respiratory Distress Syndrome |
| Q50025585 | Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. |
| Q89457536 | Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma |
| Q51389717 | Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. |
| Q42645889 | Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients |
| Q96343456 | First Trial of CRISPR-Edited T cells in Lung Cancer |
| Q45399744 | Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults |
| Q33260989 | Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients |
| Q41047644 | Herpesvirus saimiri transformation of HIV type 1 suppressive CD8+ lymphocytes from an HIV type 1-infected asymptomatic individual |
| Q45736575 | Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus. |
| Q45833544 | IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA. |
| Q36651344 | Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia |
| Q33738328 | Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia |
| Q45710911 | Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge |
| Q37262446 | Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients |
| Q38314703 | In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara |
| Q37391085 | Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation |
| Q57059973 | Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell |
| Q46454296 | La Rosa C et al (J Infect Dis 2012; 205:1294–304). |
| Q91986087 | Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia |
| Q57132855 | Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma |
| Q45403250 | Low frequency of BK virus in prostatic adenocarcinomas |
| Q33851168 | Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy |
| Q34485950 | NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. |
| Q39097305 | Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients. |
| Q37344283 | Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. |
| Q91279008 | Neurotoxicity after CTL019 in a pediatric and young adult cohort |
| Q41413246 | Noncytolytic CD8 T cell-mediated suppression of HIV replication |
| Q89169404 | Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma |
| Q40449697 | Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. |
| Q91797314 | Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia |
| Q42363154 | PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. |
| Q37117624 | Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy |
| Q92666841 | Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers |
| Q47567558 | Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. |
| Q45979494 | Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. |
| Q33523611 | Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease |
| Q34121209 | RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma |
| Q35677112 | Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion. |
| Q90374442 | Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells |
| Q47564568 | Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles |
| Q44539971 | Relevance of peptide avidity to the T cell receptor for cytomegalovirus-specific ex vivo CD8 T cell cytotoxicity |
| Q45875400 | Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients |
| Q104799444 | Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial |
| Q50026427 | Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer |
| Q92880596 | Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies |
| Q46619364 | Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. |
| Q99356573 | Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source |
| Q52016360 | Status of Cytomegalovirus Prevention and Treatment in 2000. |
| Q41918232 | Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. |
| Q89714820 | Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis |
| Q40050634 | The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. |
| Q36576683 | The CXC chemokine stromal cell-derived factor 1 is not responsible for CD8+ T cell suppression of syncytia-inducing strains of HIV-1. |
| Q112575183 | The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma |
| Q50038368 | The cytological features of CAR(T) cells |
| Q37405194 | The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation |
| Q96231836 | Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of epigenome |
| Q45896485 | Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells. |
| Q34742892 | Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. |
Search more.